Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete Remission

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 401-411

  Kurosawa, Saiko ^a   Yamaguchi, Takuhiro ^b   Uchida, Naoyuki ^c   Miyawaki, Shuichi ^d   Usuki, Kensuke ^e   Watanabe, Masato ^f   Yamashita, Takuya ^g   Kanamori, Heiwa ^h   Tomiyama, Junji ⁱ   Nawa, Yuichiro ^j   Yano, Shingo ^k   Takeuchi, Jin ^l   Yakushiji, Kazuaki ^m   Sano, Fumiaki ⁿ   Uoshima, Nobuhiko ^o   Yano, Takahiro ^p   Nannya, Yasuhito ^b   Moriuchi, Yukiyoshi ^q   Miura, Ikuo ^r   Takaue, Yoichi ^a   Fukuda, Takahiro ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^e Kanto Teishin Hospital   (Japan)

^f Yamada Hospital   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

ⁱ TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^j EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^k JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NIHON UNIVERSITY   (Japan)

^m KURUME UNIVERSITY   (Japan)

ⁿ ST MARIANNA UNIVERSITY   (Japan)

^o MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^q Sasebo Shiritsu Sogo Hospital   (Japan)

^r ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

more..

Author keywords

Acute myelogenous leukemia; Allogeneic hematopoietic cell transplantation; Elderly patients; First complete remission

Indexed keywords

BUSULFAN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GERIATRIC DISORDER; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

AGED; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79551685595     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.013     Document Type: Article

References (31)

1. Appelbaum F.R. What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. Best Pract Res Clin Haematol 2008, 21:667-675.
2. Frohling S., Schlenk R.F., Kayser S., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
3. Gardin C., Turlure P., Fagot T., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007, 109:5129-5135.
4. van der Holt B., Breems D.A., Berna Beverloo H., et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007, 136:96-105.
5. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
6. Atallah E., Cortes J., O'Brien S., et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007, 110:3547-3551.
7. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
8. Klepin H.D., Balducci L. Acute myelogenous leukemia in older adults. Oncologist 2009, 14:222-232.
9. Rowe J.M. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009, 396-405.
10. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
11. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
12. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003, 21:1480-1484.
13. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
14. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
15. Sayer H.G., Kroger M., Beyer J., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003, 31:1089-1095.
16. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
17. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003, 102:3052-3059.
18. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
19. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
20. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005, 19:916-920.
21. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
22. Lancet J.E., Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Comp Cancer Netwk 2008, 6:1017-1025.
23. Lowenberg B., Ossenkoppele G.J., van Putten W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
24. Lubbert M., Bertz H., Ruter B., et al. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
25. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184-2191.
26. Pagel J.M., Gooley T.A., Rajendran J., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009, 114:5444-5453.
27. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009, 21(Suppl 1):S3-S5.
28. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
29. Kantarjian H.M., Erba H.P., Claxton D., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010, 28:549-555.
30. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
31. Giralt S., Logan B., Rizzo D., et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007, 13:844-852.